Russell Pachynski retweeted
Not your typical conference reception! ⚾️
Great to welcome so many friends and colleagues to the ballpark tonight for our @MoffittNews #SITC26 reception.
Special thanks to the Arizona Diamondbacks (@Dbacks) for hosting us and giving our guests a behind-the-scenes look at the ght celebrating our team and the @sitcancer community.
#MoffittSITC26
Great to welcome so many friends and colleagues to the ballpark tonight for our @MoffittNews #SITC26 reception.
Special thanks to the Arizona Diamondbacks (@Dbacks) for hosting us and giving our guests a behind-the-scenes look at the ght celebrating our team and the @sitcancer community.
#MoffittSITC26
0
2
21
1,360
Russell Pachynski retweeted
Looking forward to presenting updated STX-001 clinical data at Society for Immunotherapy of Cancer Annual Meeting @sitcancer
#SITC26
@MelanomaAus @Sydney_Uni
#SITC26
@MelanomaAus @Sydney_Uni
Strand is bringing two presentations to #SITC26 this week, covering our programs STX-001 and STX-003.
Fresh off her late-breaking presentation at ESMO, @ProfGLongMIA of @MelanomaAus will be presenting updated Phase I data on STX-001’s durable, systemic anti-tumor activity.
As ram, STX-001 provided preliminary evidence that a therapy injected directly into a tumor may activate the immune system throughout the body. It helped lay the foundation for STX-003, our flagship clinical program that just dosed its first cohort of patients in ASCENT-1.
Trial principal investigator, @MLJohnsonMD2 of @SarahCannonDocs, will present on the design of ASCENT-1, which is evaluating STX-003 as a systemically delivered, programmable self-replicating mRNA engineered to switch on selectively inside tumors.
📅 Friday, November 6 | Phoenix Convention Center
📢 STX-001 oral: 4:55–5:05 pm MT, West Building-300 Level, 301BC
🧬 STX-003 poster: North Building-Lower Level, Exhibition Halls 4-6
You can find more details here: businesswire.com/news/home/2026…
We’ll see you there.
0
2
19
1,093
Always the SECOND best reception @sitcancer …after The CheckPoints party, of course 😏 @PatrickHwuMD @MoffittNews know how to throw a party!…forgot my swim trunks though 🤷🏻♂️🤣 @jasonlukemd @wolchokj @BReinfeld @ipimama123 #SITC26
2
0
5
580
Russell Pachynski retweeted
Excited for this moment! I joined @StrandTx for the mission to build programmable genetic medicines for patients in need. IL-12 has enormous promise in cancer immunotherapy, but toxicity has been a major hurdle. We're excited that STX-003 could change that. #cancer #immunotherapy
The first patients have been dosed in ASCENT-1, our Phase 1 trial of STX-003, an IV-delivered mRNA therapy designed to bring the potent immune-activating protein IL-12 to tumors throughout the body.
It’s our first systemic test of programmable mRNA, and it’s built to solve a cancer treatment for decades: the drugs powerful enough to kill tumors often damage healthy tissue, too. STX-003 is designed to sidestep that problem by selectively activating where it’s needed.
We believe it’s just the start of what the platform could make possible in this era of next-generation delivery. If this works, the same technology could carry other therapeutic proteins, opening the door to a new class of programmable medicines.
Our CEO and co-founder @DrSynbio co-founder, President, and Head of R&D @tasuku_kitada take a moment to discuss this milestone and how this trial is a test of a fundamentally new approach to treating disease.
🧬 Learn more: businesswire.com/news/home/2026…
5
6
42
3,129
Thrilled to have joined @DanaFarber and to be working with an inspiring leader in oncology, @DrChoueiri. Delighted to serve as a faculty medical oncologist and Co-Director of the @Harvard Cancer Consortium #ProstateCancer Program. Excited for this new chapter!
0
1
11
2,085
congrats Tian!! so well deserved! 🎉🤗
Promotion to Professor — an accomplishment I have worked for over many years, effective today. Thanks @suzanneconzenmd @CarlosArteagaMD & all colleagues around the world who wrote/called for me. Grateful beyond words. @DrChoueiri @montypal @AlbigesL @ERPlimackMD @Daniel_J_George
1
0
9
1,503
Russell Pachynski retweeted
What are The CheckPoints movin’ and groovin’ to this summer?
Join the journal club with the best bops: We asked @sitcancer’s 13-piece band of medical musicians for the top papers and songs of the summer
cancerletter.com/book-review/20…
Join the journal club with the best bops: We asked @sitcancer’s 13-piece band of medical musicians for the top papers and songs of the summer
cancerletter.com/book-review/20…
0
3
2
737
Russell Pachynski retweeted
Should PSMA PET–defined MFS count as a legitimate, actionable trial endpoint?
Dr. Steve Cho @UTMDAnderson at #USPCC26 says YES.
✅ PSMA PET outperforms CT/bone scan for nodal, bone, and visceral metastases
✅ In an EMBARK-eligible cohort with negative conventional imaging, 84% M1 disease
✅ Bone scans are becoming obsolete—more sensitive molecular imaging should define progression
⚠️ Use rigorous PROMISE/PSMA-RADS criteria, expert central reads, and confirm equivocal lesions
Bottom line: A new PSMA PET–detected metastasis is real progression—not “metastasis-free” simply because CT/bone scan is negative.
Written coverage by @zklaassen_md @GACancerCenter > bit.ly/4wQfuda @PCFnews
Dr. Steve Cho @UTMDAnderson at #USPCC26 says YES.
✅ PSMA PET outperforms CT/bone scan for nodal, bone, and visceral metastases
✅ In an EMBARK-eligible cohort with negative conventional imaging, 84% M1 disease
✅ Bone scans are becoming obsolete—more sensitive molecular imaging should define progression
⚠️ Use rigorous PROMISE/PSMA-RADS criteria, expert central reads, and confirm equivocal lesions
Bottom line: A new PSMA PET–detected metastasis is real progression—not “metastasis-free” simply because CT/bone scan is negative.
Written coverage by @zklaassen_md @GACancerCenter > bit.ly/4wQfuda @PCFnews
0
10
22
1,648
Russell Pachynski retweeted
🧬 Capivasertib + abiraterone offers a precision-medicine alternative to chemotherapy-based triplet therapy in PTEN-deficient metastatic APMN/S prostate cancer.
At #USPCC26, Dr. Russell Szmulewitz @UChicagoMed highlighted CAPItello-281: in 1,012 patients with PTEN-deficient de , capivasertib improved median rPFS from 25.7 to 33.2 months, with the largest apparent benefit in complete PTEN loss. OS is still immature, while toxicity—including diarrhea, hyperglycemia, rash, and anemia—was manageable but led to discontinuation in ~18%.
Bottom line: For high-volume, de novo PTEN-deficient disease, capivasertib + abiraterone targets a poor-prognosis biology at the earliest opportunity—without requiring docetaxel.
Written coverage by @zklaassen_md on UroToday > bit.ly/4wdPyHk
At #USPCC26, Dr. Russell Szmulewitz @UChicagoMed highlighted CAPItello-281: in 1,012 patients with PTEN-deficient de , capivasertib improved median rPFS from 25.7 to 33.2 months, with the largest apparent benefit in complete PTEN loss. OS is still immature, while toxicity—including diarrhea, hyperglycemia, rash, and anemia—was manageable but led to discontinuation in ~18%.
Bottom line: For high-volume, de novo PTEN-deficient disease, capivasertib + abiraterone targets a poor-prognosis biology at the earliest opportunity—without requiring docetaxel.
Written coverage by @zklaassen_md on UroToday > bit.ly/4wdPyHk
0
17
26
2,170
Russell Pachynski retweeted
FDA approval of capivasertib with abiraterone and prednisone in PTEN-deficient androgen pathway modulation-naïve or -sensitive #ProstateCancer. @neerajaiims @huntsmancancer hosts an expert panel discussion with @EHeath4100 @MayoClinic, @hoperugo @cityofhope, and @Daniel_J_George tello-281 trial. #WatchNow > bit.ly/4uIgVZh @AstraZeneca
0
4
7
1,137
Russell Pachynski retweeted
Pluvicto® Approved for PSMA-Positive mHSPC: Bringing Radioligand Therapy Earlier in the Disease Course. @sartor_oliver @EJHospital joins @PhillipKooMD @PCFnews to discuss the @FDA approval of Pluvicto™ (lutetium-177 PSMA-617) in metastatic hormone-sensitive prostate cancer based ow on UroToday > bit.ly/4c8aB6L @DrScottTagawa @Novartis
0
6
14
2,407
Russell Pachynski retweeted
Just in👉today @US_FDA approved Pluvicto (Lutetium-177)for PSMA+ metastatic androgen pathway modulation-sensitive #prostatecancer (mAPMS/mHSPC), based on the results of ph3 PSMAddition trial👇 @PCF_Science @urotoday @OncoAlert Congrats @DrScottTagawa & team
3
41
95
19,174
Russell Pachynski retweeted
WATCH: Jeff M. Michalski, MD, MBA, FACR, FASTRO, discusses the future of radiopharmaceuticals in prostate cancer. #oncology #pcsm #prostatecancer
1
3
4
1,055
Russell Pachynski retweeted
Thanks to @SurvivorNetTeam for the interview - a new mechanism of action drug for prostate cancer patients is great! Now we need to figure out how to make it work better for more patients! @SitemanCenter @WashUOncology @WashUDeptMed @Pachynski_Lab
The FDA approved a first-of-its-kind drug for aggressive prostate cancer. @washumedicine medical oncologist Russell Pachynski, MD, of Siteman tells @SurvivorNetTeam what it means for patients. survivornet.com/articles/the-f…
0
1
3
664
Russell Pachynski retweeted
The FDA approved a first-of-its-kind drug for aggressive prostate cancer. @washumedicine medical oncologist Russell Pachynski, MD, of Siteman tells @SurvivorNetTeam what it means for patients. survivornet.com/articles/the-f…
0
3
6
1,197
Amazing leadership @mpndoc congrats!!
Delighted to share that our NHLBI-supported Molecular Hematology T32 training grant has been officially renewed! 🎉Our program, now funded through Year 55, continues a long tradition of excellence in hematology research training @WashUHematology @WashUDeptMed @washumedicine. 🤩
1
0
3
955
Thanks to @SurvivorNetTeam for the interview - a new mechanism of action drug for prostate cancer patients is great! Now we need to figure out how to make it work better for more patients! @SitemanCenter @WashUOncology @WashUDeptMed @Pachynski_Lab
The FDA approved a first-of-its-kind drug for aggressive prostate cancer. @washumedicine medical oncologist Russell Pachynski, MD, of Siteman tells @SurvivorNetTeam what it means for patients. survivornet.com/articles/the-f…
0
1
3
664
and @WalterStadler5 what a great group! 🤩🤩🤩
Excited to be at our @cityofhope GU retreat this Saturday morning, led by our amazing GU Division Chief @TDorffOnc! Great comments on institutional growth & expansion from Dr. John Carpten, our CC Director, to kick things off! Looking fwd to our keynote lecture from @virajmaster @Emoy & updates from @WesleyYipMD, @VirginiaSunPhD, @WalterStadler5 , @AliZUroOnc, @yunroseli, @alexzhuDO, @charlesbnguyen & others!
1
2
9
2,162
Russell Pachynski retweeted
@TotalHealthConf Hawai’i! 🎉🤗…amazing lineup including GU stars 🤩🤩 @PBarataMD @bilenma 10/10 recommend!
1
2
6
795